Antiemetics Market By Drug Type (Antihistamines, Serotonin Receptor Antagonists, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Anticholinergics, Other Drug Types), By Application (Chemotherapy, Post Operative Surgery, Pregnancy and Gatroenteritis, Other Applications), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031, registering a CAGR of 6.1% from 2022 to 2031.
Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.
Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.
Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.
Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.
However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.
The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
Antihistamines
Serotonin Receptor Antagonists
Dopamine Receptor Antagonists
Neurokinin Receptor Antagonists
Anticholinergics
Other Drug Types
By Application
Chemotherapy
Post Operative Surgery
Pregnancy and Gatroenteritis
Other Applications
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
GlaxoSmithKline Plc
Sanofi
Novartis AG
Pfizer Inc
Merck & Co. Inc
Dr. Reddy’s Laboratories Ltd
Cipla
Johnson & Johnson
Torrent Pharmaceuticals Ltd
Acacia Pharma Group
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Antihistamines
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Serotonin Receptor Antagonists
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Dopamine Receptor Antagonists
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Neurokinin Receptor Antagonists
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Anticholinergics
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- 4.7 Other Drug Types
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
- CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Post Operative Surgery
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Pregnancy and Gatroenteritis
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Other Applications
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Retail Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Hospital Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: ANTIEMETICS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Type
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Type
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Type
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Type
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Type
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Type
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Type
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Type
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Type
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Type
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Type
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Drug Type
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Drug Type
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Drug Type
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Drug Type
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Type
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Type
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Type
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Type
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Type
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Type
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Type
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 GlaxoSmithKline Plc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Sanofi
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Novartis AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Pfizer Inc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Merck & Co. Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Dr. Reddy’s Laboratories Ltd
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Cipla
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Johnson & Johnson
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Torrent Pharmaceuticals Ltd
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Acacia Pharma Group
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 2. ANTIEMETICS MARKET, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. ANTIEMETICS MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. ANTIEMETICS MARKET, FOR SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. ANTIEMETICS MARKET FOR SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. ANTIEMETICS MARKET, FOR DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. ANTIEMETICS MARKET FOR DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. ANTIEMETICS MARKET, FOR NEUROKININ RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. ANTIEMETICS MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. ANTIEMETICS MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. ANTIEMETICS MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. ANTIEMETICS MARKET, FOR OTHER DRUG TYPES, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. ANTIEMETICS MARKET FOR OTHER DRUG TYPES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 15. ANTIEMETICS MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. ANTIEMETICS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. ANTIEMETICS MARKET, FOR POST OPERATIVE SURGERY, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. ANTIEMETICS MARKET FOR POST OPERATIVE SURGERY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. ANTIEMETICS MARKET, FOR PREGNANCY AND GATROENTERITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. ANTIEMETICS MARKET FOR PREGNANCY AND GATROENTERITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. ANTIEMETICS MARKET, FOR OTHER APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. ANTIEMETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. GLOBAL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 24. ANTIEMETICS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. ANTIEMETICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. ANTIEMETICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. ANTIEMETICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. ANTIEMETICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. ANTIEMETICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. ANTIEMETICS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 34. NORTH AMERICA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 35. U.S. ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 36. U.S. ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 37. U.S. ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. CANADA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 39. CANADA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 40. CANADA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. MEXICO ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 42. MEXICO ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 43. MEXICO ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 45. EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 46. EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. EUROPE ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 48. GERMANY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 49. GERMANY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 50. GERMANY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 51. FRANCE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 52. FRANCE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 53. FRANCE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 54. UK ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 55. UK ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 56. UK ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. ITALY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 58. ITALY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 59. ITALY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. SPAIN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 61. SPAIN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 62. SPAIN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 70. CHINA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 71. CHINA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 72. CHINA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. JAPAN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 74. JAPAN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 75. JAPAN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. INDIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 77. INDIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 78. INDIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 81. AUSTRALIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 88. LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 89. LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 90. LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 91. LAMEA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 104.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 105.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 106.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 107.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 108.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 109.SANOFI: COMPANY SNAPSHOT
- TABLE 110.SANOFI: OPERATING SEGMENTS
- TABLE 111.SANOFI: PRODUCT PORTFOLIO
- TABLE 112.SANOFI: NET SALES,
- TABLE 113.SANOFI: KEY STRATERGIES
- TABLE 114.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 115.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 116.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 117.NOVARTIS AG: NET SALES,
- TABLE 118.NOVARTIS AG: KEY STRATERGIES
- TABLE 119.PFIZER INC: COMPANY SNAPSHOT
- TABLE 120.PFIZER INC: OPERATING SEGMENTS
- TABLE 121.PFIZER INC: PRODUCT PORTFOLIO
- TABLE 122.PFIZER INC: NET SALES,
- TABLE 123.PFIZER INC: KEY STRATERGIES
- TABLE 124.MERCK & CO. INC: COMPANY SNAPSHOT
- TABLE 125.MERCK & CO. INC: OPERATING SEGMENTS
- TABLE 126.MERCK & CO. INC: PRODUCT PORTFOLIO
- TABLE 127.MERCK & CO. INC: NET SALES,
- TABLE 128.MERCK & CO. INC: KEY STRATERGIES
- TABLE 129.DR. REDDY’S LABORATORIES LTD: COMPANY SNAPSHOT
- TABLE 130.DR. REDDY’S LABORATORIES LTD: OPERATING SEGMENTS
- TABLE 131.DR. REDDY’S LABORATORIES LTD: PRODUCT PORTFOLIO
- TABLE 132.DR. REDDY’S LABORATORIES LTD: NET SALES,
- TABLE 133.DR. REDDY’S LABORATORIES LTD: KEY STRATERGIES
- TABLE 134.CIPLA: COMPANY SNAPSHOT
- TABLE 135.CIPLA: OPERATING SEGMENTS
- TABLE 136.CIPLA: PRODUCT PORTFOLIO
- TABLE 137.CIPLA: NET SALES,
- TABLE 138.CIPLA: KEY STRATERGIES
- TABLE 139.JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 140.JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 141.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 142.JOHNSON & JOHNSON: NET SALES,
- TABLE 143.JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 144.TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
- TABLE 145.TORRENT PHARMACEUTICALS LTD: OPERATING SEGMENTS
- TABLE 146.TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
- TABLE 147.TORRENT PHARMACEUTICALS LTD: NET SALES,
- TABLE 148.TORRENT PHARMACEUTICALS LTD: KEY STRATERGIES
- TABLE 149.ACACIA PHARMA GROUP: COMPANY SNAPSHOT
- TABLE 150.ACACIA PHARMA GROUP: OPERATING SEGMENTS
- TABLE 151.ACACIA PHARMA GROUP: PRODUCT PORTFOLIO
- TABLE 152.ACACIA PHARMA GROUP: NET SALES,
- TABLE 153.ACACIA PHARMA GROUP: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.ANTIEMETICS MARKET SEGMENTATION
- FIGURE 2.ANTIEMETICS MARKET,2021-2031
- FIGURE 3.ANTIEMETICS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.ANTIEMETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.ANTIEMETICS MARKET,BY DRUG TYPE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEROTONIN RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DOPAMINE RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUROKININ RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICHOLINERGICS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHER DRUG TYPES ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 19.ANTIEMETICS MARKET,BY APPLICATION,2021(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF POST OPERATIVE SURGERY ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND GATROENTERITIS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 24.ANTIEMETICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
- FIGURE 28.ANTIEMETICS MARKET BY REGION,2021
- FIGURE 29.U.S. ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 30.CANADA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 31.MEXICO ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 32.GERMANY ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 33.FRANCE ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 34.UK ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 35.ITALY ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 36.SPAIN ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 37.REST OF EUROPE ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 38.CHINA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 39.JAPAN ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 40.INDIA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 41.AUSTRALIA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH KOREA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF ASIA-PACIFIC ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 44.BRAZIL ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 45.SAUDI ARABIA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 46.SOUTH AFRICA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 47.REST OF LAMEA ANTIEMETICS MARKET,2021-2031($MILLION)
- FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 52.COMPETITIVE DASHBOARD
- FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
- FIGURE 55.SANOFI.: NET SALES ,($MILLION)
- FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 57.PFIZER INC.: NET SALES ,($MILLION)
- FIGURE 58.MERCK & CO. INC.: NET SALES ,($MILLION)
- FIGURE 59.DR. REDDY’S LABORATORIES LTD.: NET SALES ,($MILLION)
- FIGURE 60.CIPLA.: NET SALES ,($MILLION)
- FIGURE 61.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
- FIGURE 62.TORRENT PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
- FIGURE 63.ACACIA PHARMA GROUP.: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook